Li, Y. et al. B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J. Immunol. 181, 2961-2972

Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
The Journal of Immunology (Impact Factor: 5.36). 10/2008; 181(5):2961-72. DOI: 10.4049/jimmunol.181.5.2961
Source: PubMed

ABSTRACT MRL/lpr mice develop a spontaneous systemic lupus erythematosus-like autoimmune syndrome due to a dysfunctional Fas receptor, with contributions from other less well-defined genetic loci. The removal of B cells by genetic manipulation not only prevents autoantibody formation, but it also results in substantially reduced T cell activation and kidney inflammation. To determine whether B cell depletion by administration of Abs is effective in lupus mice with an intact immune system and established disease, we screened several B cell-specific mAbs and found that a combination of anti-CD79alpha and anti-CD79beta Abs was most effective at depleting B cells in vivo. Anti-CD79 therapy started at 4-5 mo of age in MRL/lpr mice significantly decreased B cells (B220(+)CD19(+)) in peripheral blood, bone marrow, and spleens. Treated mice also had a significant increase in the number of both double-negative T cells and naive CD4(+) T cells, and a decreased relative abundance of CD4(+) memory cells. Serum anti-chromatin IgG levels were significantly decreased compared with controls, whereas serum anti-dsDNA IgG, total IgG, or total IgM were unaffected. Overall, survival was improved with lower mean skin scores and significantly fewer focal inflammatory infiltrates in submandibular salivary glands and kidneys. Anti-CD79 mAbs show promise as a potential treatment for systemic lupus erythematosus and as a model for B cell depletion in vivo.

Download full-text


Available from: John Cambier, Dec 22, 2014
  • Source
    • "MRL-MpJFas lpr (MRL/lpr) mice have a mutation in the Fas gene and develop a disease similar to SLE that is characterised by glomerulonephritis, vasculitis, splenomegaly, hypergammaglobulinemia, and the production of anti-dsDNA antibodies [21]. In this mouse strain, B cell elimination using an anti-CD79 antibody decreased the manifestation of SLE-like symptoms, demonstrating the importance of B cells in SLE physiopathology [22] [23]. B cells develop from hematopoietic stem cells in the bone marrow through a series of differentiation stages. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prolactin (PRL) plays an important role in modulating the immune response. In B cells, PRL enhances antibody production, including antibodies with self-specificity. In this study, our aims were to determine the level of PRL receptor expression during bone-marrow B-cell development and to assess whether the presence of high PRL serum concentrations influences absolute numbers of developing populations and disease outcome in lupus-prone murine models. We observed that the PRL-receptor is expressed in early bone-marrow B-cell; the expression in lupus-prone mice, which had the highest level of expression in pro-B cells and immature cells, differed from that in wild-type mice. These expression levels did not significantly change in response to hyperprolactinemia; however, populations of pro-B and immature cells from lupus-prone strains showed a decrease in the absolute numbers of cells with high PRL-receptor expression in response to PRL. Because immature self-reactive B cells are constantly being eliminated, we assessed the expression of survival factor BIRC5, which is more highly expressed in both pro-B and immature B-cells in response to PRL and correlates with the onset of disease. These results identify an important role of PRL in the early stages of the B-cell maturation process: PRL may promote the survival of self-reactive clones.
    Clinical and Developmental Immunology 12/2013; 2013:287469. DOI:10.1155/2013/287469 · 2.93 Impact Factor
  • Source
    • "those coupled to potent cytotoxic agents, are effective at killing human B cell lymphoma cells both in vitro and in mouse chimeras (Polson et al. 2007). Anti-mouse CD79 mAbs have also been shown to be effective in depleting B cells and at ameliorating autoimmune disease in MRL/lpr mice (Li et al. 2008). To engineer recombinant anti-CD79 antibodies with additional effector functions in mice, we have cloned and sequenced the full-length IG heavy and light chains of an Armenian hamster (Cricetulus migratorius) anti-mouse CD79B reagent antibody (clone HM79-16 or HM79b) (in the absence of genomic information, this antibody is designated as IgG2, λ1 by the companies which distribute it) (Koyama et al. 1997). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-CD79 antibodies have been effective at targeting B cell lymphoma cells and depleting B cells in animal models. In order to engineer recombinant antibodies with additional effector functions in mice, we cloned and sequenced the full-length cDNAs of the heavy and light chain of a hamster anti-mouse CD79B antibody. Although hamster antibodies represent a unique source of monoclonal antibodies against mouse, rat, and human antigens, sequence information of hamster immunoglobulins (IG) is sparse. Here, we report a new hamster (Cricetulus migratorius) IG lambda constant (IGLC) gene region that is most homologous to mouse IGLC2 and IGLC3.
    Immunogenetics 04/2013; DOI:10.1007/s00251-013-0698-5 · 2.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Here we review extant recent findings regarding the multiple roles of B cells in type 1 diabetes (T1D) and discuss how autoreactive B cells may become activated by a breach in B cell tolerance, and thereby initiate disease. Finally, we discuss the use of B cell-targeted therapies for treatment of autoimmunity. Anti-CD20-specific depletion of B cells prevents and reverses diabetes in human CD20/non-obese diabetic (NOD) mice. Correspondingly, in nontransgenic NOD mice, B cells are effectively depleted with high dose antimouse CD20 mAbs of varying isotypes, and this also prevents diabetes in more than 60% of the mice when administered early, and significantly delays disease in 15-week-old animals. A separate study revealed that targeting B cells with anti-CD22/cal monoclonal antibody therapy delays diabetes onset in prediabetic NOD mice and restores normoglycemia in new-onset hyperglycemic NOD mice. In humans, a clinical trial of rituximab in new onset type 1 diabetics has yielded promising preliminary findings. B cells are major players in T1D in humans, and clearly essential for disease development in the NOD mouse model of T1D. In this review, we discuss the silencing of autoreactive B cells and how failure of this process may contribute to autoimmunity. Further, we describe the most recent advances in studies of therapeutic effects of B cell depletion in T1D, and provide recent data indicating the diverse functions by which B cells may mediate disease.
    Current opinion in endocrinology, diabetes, and obesity 07/2009; 16(4):293-8. DOI:10.1097/MED.0b013e32832e06a7 · 3.77 Impact Factor
Show more